Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BERNARD BEUTE

Allopathic & Osteopathic Physicians Radiology Diagnostic Radiology

NPI
1598700437
CMS profile
1006431
Location
KINNELON, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$350,860.00

189 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $350,860.00 189

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $346,870.00 178
PFIZER INC. $3,990.00 11

Page 3 of 4; records 101–150 of 189 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BERNARD BEUTE

NPI 1598700437 · CMS profile ID 1006431

Allopathic & Osteopathic Physicians / Radiology / Diagnostic Radiology

KINNELON, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 189 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598700437?year=2020&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BERNARD BEUTE, NPI 1598700437, CMS profile ID 1006431. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 189 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598700437?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). BERNARD BEUTE, NPI 1598700437, CMS profile ID 1006431. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 189 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598700437?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
BERNARD BEUTE, NPI 1598700437, CMS profile ID 1006431, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 189 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1598700437?year=2020&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

189 matching records · $350,860.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 189 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 189.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $3,540.0006/04/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622757 CMS
Merck Sharp & Dohme Corporation $1,860.0006/04/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622873 CMS
Merck Sharp & Dohme Corporation $2,340.0006/04/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747623005 CMS
Merck Sharp & Dohme Corporation $240.0006/04/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747623007 CMS
Merck Sharp & Dohme Corporation $4,620.0006/04/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747623015 CMS
Merck Sharp & Dohme Corporation $2,790.0006/04/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747623147 CMS
Merck Sharp & Dohme Corporation $660.0006/04/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747624499 CMS
Merck Sharp & Dohme Corporation $1,530.0006/04/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747624615 CMS
Merck Sharp & Dohme Corporation $3,780.0006/04/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747624715 CMS
PFIZER INC. $300.0006/04/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743629833 CMS
Merck Sharp & Dohme Corporation $60.0005/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622221 CMS
Merck Sharp & Dohme Corporation $6,720.0005/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622229 CMS
Merck Sharp & Dohme Corporation $1,260.0005/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622517 CMS
Merck Sharp & Dohme Corporation $1,440.0005/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622621 CMS
Merck Sharp & Dohme Corporation $3,720.0005/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622761 CMS
Merck Sharp & Dohme Corporation $1,560.0005/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622865 CMS
Merck Sharp & Dohme Corporation $1,650.0005/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622869 CMS
Merck Sharp & Dohme Corporation $2,340.0005/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747623003 CMS
Merck Sharp & Dohme Corporation $2,780.0005/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747623009 CMS
Merck Sharp & Dohme Corporation $4,860.0005/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747623019 CMS
Merck Sharp & Dohme Corporation $60.0005/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747623167 CMS
Merck Sharp & Dohme Corporation $300.0005/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747623207 CMS
Merck Sharp & Dohme Corporation $990.0005/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747624589 CMS
Merck Sharp & Dohme Corporation $2,340.0005/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747625033 CMS
Merck Sharp & Dohme Corporation $260.0005/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747625035 CMS
PFIZER INC. $150.0005/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743630371 CMS
Merck Sharp & Dohme Corporation $600.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622225 CMS
Merck Sharp & Dohme Corporation $690.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622231 CMS
Merck Sharp & Dohme Corporation $8,760.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622275 CMS
Merck Sharp & Dohme Corporation $1,080.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622471 CMS
Merck Sharp & Dohme Corporation $120.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622477 CMS
Merck Sharp & Dohme Corporation $150.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622625 CMS
Merck Sharp & Dohme Corporation $360.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622759 CMS
Merck Sharp & Dohme Corporation $4,520.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622817 CMS
Merck Sharp & Dohme Corporation $2,070.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622875 CMS
Merck Sharp & Dohme Corporation $2,250.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622997 CMS
Merck Sharp & Dohme Corporation $2,280.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622999 CMS
Merck Sharp & Dohme Corporation $4,740.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747623017 CMS
Merck Sharp & Dohme Corporation $300.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747623203 CMS
Merck Sharp & Dohme Corporation $300.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747623205 CMS
Merck Sharp & Dohme Corporation $3,000.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747623209 CMS
Merck Sharp & Dohme Corporation $1,080.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747624135 CMS
Merck Sharp & Dohme Corporation $300.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747625243 CMS
PFIZER INC. $540.0003/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743629835 CMS
Merck Sharp & Dohme Corporation $6,570.0002/28/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622227 CMS
Merck Sharp & Dohme Corporation $8,580.0002/28/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622273 CMS
Merck Sharp & Dohme Corporation $900.0002/28/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622277 CMS
Merck Sharp & Dohme Corporation $390.0002/28/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622811 CMS
Merck Sharp & Dohme Corporation $420.0002/28/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622815 CMS
Merck Sharp & Dohme Corporation $180.0002/28/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747622871 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $170,070.00 102
PY2020 $350,860.00 189
PY2021 $249,960.00 176
PY2023 $615.00 6
PY2024 $1,500.00 7

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $79,900.39 23
PY2024 Recipient $28,546.26 8
PY2024 Principal investigator $912.02 2
PY2023 Recipient $136,495.00 14
PY2022 Recipient $103,060.00 12
PY2021 Recipient $53,835.00 10
PY2020 Recipient $17,220.00 10
PY2020 Principal investigator $60.00 1
PY2019 Recipient $14,550.00 4
PY2019 Principal investigator $120.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient E.R. Squibb & Sons, L.L.C. $90.00 10/03/2025 Covered Recipient Physician A Phase 1/2, Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) No dispute reported 06/30/2026 1236002355
Recipient E.R. Squibb & Sons, L.L.C. $3,135.00 10/03/2025 Covered Recipient Physician A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% No dispute reported 06/30/2026 1236002367
Recipient E.R. Squibb & Sons, L.L.C. $210.00 09/04/2025 Covered Recipient Physician A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigators Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer No dispute reported 06/30/2026 1236002359
Recipient E.R. Squibb & Sons, L.L.C. $6,900.00 09/04/2025 Covered Recipient Physician A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer No dispute reported 06/30/2026 1236002365
Recipient E.R. Squibb & Sons, L.L.C. $530.00 08/08/2025 Covered Recipient Physician A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma after Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 1236002363
Recipient E.R. Squibb & Sons, L.L.C. $8,145.00 08/08/2025 Covered Recipient Physician A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigators Choice in Participants with Relapsed/Refractory Follicular Lymphoma who have Received at least 1 Prior Line of Systemic Therapy No dispute reported 06/30/2026 1236002373
Recipient E.R. Squibb & Sons, L.L.C. $3,915.00 08/08/2025 Covered Recipient Physician A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge No dispute reported 06/30/2026 1236002375
Recipient GlaxoSmithKline, LLC. $318.85 07/15/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192173584
Recipient E.R. Squibb & Sons, L.L.C. $7,965.00 06/06/2025 Covered Recipient Physician A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of BMS-986369 in Participants with Relapsed or Refractory T-cell Lymphomas in Japan No dispute reported 06/30/2026 1236002349
Recipient GlaxoSmithKline, LLC. $1,629.45 05/13/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192173592
Recipient E.R. Squibb & Sons, L.L.C. $450.00 05/05/2025 Covered Recipient Physician A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors No dispute reported 06/30/2026 1236002371
Recipient GlaxoSmithKline, LLC. $1,817.00 04/15/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192115498
Recipient E.R. Squibb & Sons, L.L.C. $3,930.00 04/03/2025 Covered Recipient Physician A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer No dispute reported 06/30/2026 1236002353
Recipient E.R. Squibb & Sons, L.L.C. $495.00 04/03/2025 Covered Recipient Physician A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy No dispute reported 06/30/2026 1236002357
Recipient E.R. Squibb & Sons, L.L.C. $5,190.00 04/03/2025 Covered Recipient Physician A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma No dispute reported 06/30/2026 1236002369
Recipient GlaxoSmithKline, LLC. $1,340.57 03/11/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192173588
Recipient GlaxoSmithKline, LLC. $1,625.00 02/12/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192115504
Recipient E.R. Squibb & Sons, L.L.C. $165.00 02/06/2025 Covered Recipient Physician PET ( Positron Emission Tomography) Response Criteria in Solid Tumors No dispute reported 06/30/2026 1236002377
Recipient GlaxoSmithKline, LLC. $1,408.52 01/15/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192115492
Recipient E.R. Squibb & Sons, L.L.C. $25,025.00 01/03/2025 Covered Recipient Physician A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1236002351
Recipient E.R. Squibb & Sons, L.L.C. $600.00 01/03/2025 Covered Recipient Physician A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon Cancer No dispute reported 06/30/2026 1236002361
Recipient Eli Lilly and Company $2,946.00 01/03/2025 Covered Recipient Physician A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) No dispute reported 06/30/2026 1187871649
Recipient Eli Lilly and Company $2,070.00 01/03/2025 Covered Recipient Physician A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) No dispute reported 06/30/2026 1187872077